The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | IELSG30: treating primary testicular DLBCL
Annarita Conconi, MD, Ospedale degli Infermi, Biella, Italy, summarizes the 5-year results of the Phase II IELSG30 trial (NCT00945724) assessing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), intravenous methotrexate, liposomal cytarabine, and scrotal irradiation in patients with primary diffuse large B-cell lymphoma (DLBCL) of the testis. DLBCL of the testis has a risk of central nervous system (CNS) relapse and treatment resulted in a high progression-free survival (PFS) rate, with no CNS relapses reported. Late relapses remain a problem and PD-L1 inhibitors may prevent late relapses. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
